Reata pharmaceuticals, inc. (RETA)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16
Operating activities
Net loss

-309,955

-290,170

-128,811

-119,951

-113,782

-80,546

-71,641

-53,111

-36,491

-47,671

-35,129

-23,722

-13,067

-6,227

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation

1,040

932

779

626

500

431

412

404

408

437

481

554

624

682

0

0

0

Amortization of debt issuance costs and implied interest

1,524

1,374

1,356

1,356

1,168

888

0

0

0

-

-

-

-

-

-

-

-

Stock-based compensation expense

41,461

26,381

16,857

14,223

12,292

10,550

9,583

8,382

7,412

6,530

5,646

4,817

3,681

2,367

0

0

0

Changes in operating assets and liabilities:
Income tax receivable

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Amounts earned or due from collaboration agreements

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

Prepaid expenses and other current assets

734

469

1,749

3,397

913

1,154

1,387

1,029

462

778

-986

-121

1,226

1,218

0

0

0

Other assets

-1,411

-410

-26

-15

247

-20

-264

-263

-523

519

0

0

0

-

-

-

-

Accounts payable

9,076

-2,114

-1,418

2,221

2,498

1,955

2,579

-503

461

-1,763

1,125

1,244

-5

299

0

0

0

Accrued direct research, other current, and long-term liabilities

6,138

11,975

5,023

5,944

5,642

4,417

10,519

11,780

9,525

6,973

7,501

4,106

1,953

3,080

0

0

0

Payable to collaborators

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Federal income tax receivable/payable

-

-

-

-

-

-

-

-

-

-

-

-

-

31,926

0

0

0

Deferred revenue

-209,775

-216,332

-31,336

-27,204

-21,966

-21,351

-22,961

-31,696

-41,485

-46,603

-49,594

-49,594

-49,595

-49,730

0

0

0

Net cash used in operating activities

-263,592

-251,151

-139,273

-95,796

-88,494

-83,783

-71,019

-93,192

-85,219

-83,256

-69,659

-46,911

-42,134

-19,259

0

0

0

Purchases of property and equipment

1,598

2,673

2,729

2,503

1,688

679

506

555

461

344

267

230

358

340

0

0

0

Net cash used in investing activities

-1,598

-2,673

-2,729

-2,503

-1,688

-679

-505

-554

-460

-343

-266

-229

-357

-339

0

0

0

Payments on deferred offering costs

-

-

-

-

-

-

-

-

-

-

-

-

-

2,607

0

0

0

Proceeds from long-term debt

-

-

-

-

-

-

-

-

-

20,000

0

0

0

-

-

-

-

Payments on deferred issuance costs

-

-

-

-

-

2,290

2,562

2,513

367

524

0

0

0

-

-

-

-

Exercise of options

9,771

13,400

6,829

7,138

6,604

1,885

1,793

1,248

751

660

0

0

0

-

-

-

-

Other shareholder transactions

0

107

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Payment of capital lease obligation

-

-

-

-

-

-

-

-

-

-

-

-

45

45

0

0

0

Net cash provided by financing activities

576,622

580,358

6,966

240,072

297,301

292,472

292,109

167,246

108,940

128,647

128,865

19,951

83,314

62,322

0

0

0

Net decrease in cash and cash equivalents

311,432

326,534

-135,036

141,773

207,119

208,010

220,585

73,500

23,261

45,048

58,940

-27,189

40,823

42,724

0

0

0

Supplemental disclosures
Cash paid for interest

9,329

8,207

8,252

7,540

6,348

4,741

3,152

2,153

1,604

1,164

0

0

0

-

-

-

-

Unpaid debt issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

Accrued deferred offering cost

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Non-cash activity:
Right-of-use assets obtained in exchange for lease obligations

-568

9,068

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Income taxes paid

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Purchases of equipment in accounts payable, accrued direct research, other current, and long-term liabilities

950

302

606

621

1,168

492

0

0

0

-

-

-

-

-

-

-

0